Condition
Hyperphenylalaninemia
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results80% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03519711Phase 1Completed
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia
NCT01619722Completed
Study of a National Cohort of Adult Patients With Phenylketonuria
NCT02212288Completed
Antioxidant Signature in Adult Patients With Phenylketonuria
NCT01869972Completed
Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia
NCT01541397Not ApplicableTerminatedPrimary
Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy
Showing all 5 trials